Shares of the clinical-stage biotech bluebird bio (NASDAQ:BLUE) rose by as much as 23.9% in pre-market trading today. The catalyst? The company reported that its CAR-T candidate, bb2121, produced “unprecedented responses” in patients with advanced forms of the deadly blood cancer known as multiple myeloma in a small, early-stage dose-escalation study.

https://www-fool-com.cdn.ampproject.org/c/s/www.fool.com/amp/investing/2017/12/11/bluebird-bio-stock-soars-on-unprecedented-blood-ca.aspx